Currently, there is a growing recognition that the PI3K/AKT/mTOR pathway emerges as a distinct intracellular signaling pathway in driving prostate cancer cells resistance to androgen deprivation therapy and triggering tumor progress in the setting of castrated levels of testosterone [14,15], which is deregulated in 42% of locally advanced prostate cancers and nearly 100% of advanced prostate cancers [16,17]. This evidence concerns the gene AKT1 and prostate carcinoma.